TRT typically requires evaluation, prescription, labs, and ongoing monitoring.

TRT delivers testosterone from outside the body (injection, gel, patch, pellet) and requires medical management.

Outside testosterone suppresses the body's own production.

TRT can limit sperm production and shrink the testicles.

Injected testosterone drove sperm counts to zero (azoospermia) in roughly 94 to 98 percent of men within six months, and a crash is near-inevitable until natural production restarts.

After long-term use or very low starting levels, natural production may not fully recover.

TRT monthly cost ranges roughly $40 to $1,000+, annual roughly $500 to $12,000+; telehealth subscriptions commonly $150 to $250 per month; mid-range cash-pay about $2,000 to $5,000 per year.

Injections roughly $20 to $100 per month, gels roughly $200 to $500 per month, pellets $1,000+ per insertion, plus recurring labs and visits.

FDA boxed warning: secondary exposure to topical testosterone has caused virilization in children; women and children should avoid contact with unwashed or unclothed application sites.

Virilization signs from secondary exposure in women can include excess hair growth and voice deepening.

TRT risks include acne and skin reactions, worsening sleep apnea, prostate growth (and growth of an existing prostate cancer), breast enlargement, limiting sperm production or shrinking the testicles, and excess red blood cell production that raises clot risk.

Possible increased heart-disease risk (more research needed) and a link to blood clots in veins.

If TRT is stopped, testosterone levels typically fall back toward baseline, and stopping should be managed with a provider.

Testosterone dependence: TRT shuts down natural production; coming off after long-term use can mean 6 to 18 months or more of significantly worse symptoms, returning to pretreatment level at best.

Injected testosterone caused azoospermia in roughly 94 to 98 percent of men within six months; a post-stop crash is near-inevitable until natural production restarts.

Withdrawal is not a one-to-two-week event; full recovery of the hormone axis commonly takes 3 to 6 months or longer.

After long-term use or very low starting levels, natural production may never fully return to baseline.

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and impairs sperm production; both the AUA and the Endocrine Society recommend against using testosterone in men who want to preserve fertility.

AUA guideline: men interested in fertility should have a reproductive evaluation before treatment, and the long-term impact of exogenous testosterone on sperm production should be discussed.

In a small randomized placebo-controlled pilot from the University of Siena, men who received active bright-light treatment reported roughly three times greater improvement in sexual satisfaction than the placebo group (about 2 to 6.3 on a 10-point scale, versus 2.7 for placebo), and their testosterone rose from about 2.1 to 3.6 ng/ml over two weeks while the placebo group showed no significant change. It is a small, preliminary study that has not been replicated at scale.

Low testosterone is frequently associated with treatable conditions rather than permanent failure, including diabetes, pituitary disorders, chronic narcotic or corticosteroid use, and other documented medical conditions worth evaluating before treatment.